Ankylosing spondylitis is an idiopathic disease, associated with HLA-B27, IL23R and ERAP1 genes. Usually, fewer people get affected with ankylosing spondylitis irrespective of activation of genes. Blood test, X-ray test, Magnetic Resonance Imaging (MRI) and physical investigations are some of the ways to effectively diagnose the disease. The disease begins with the inflammation in joints in the vertebrae and pelvic bones and spine. The environmental factors are believed to be the most important risk factor for increasing the incidence of the disease. The primary symptoms include back pain and stiffness.
Considerable growth in therapeutic pipeline of ankylosing spondylitis is attributed to the increase in prevalence of the disease among teens as well as young adult patients. Researchers have not been able to identify the actual cause of the disease. Novel anti-inflammatory agents and pain killers are being developed that are primarily responsible for the growth of therapeutics pipeline for ankylosing spondylitis.
In June 2015, UniQuest Pty Ltd signed a collaborative agreement with Janssen Cilag Pty Limited for development and commercialization of small molecule modulators of a biological target identified by the University of Queensland, as an important factor for the treatment of ankylosing spondylitis, and potentially psoriasis and inflammatory bowel disease. In December 2016, Janssen Biotech, Inc. confirmed the submission of two Supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) seeking approval of SIMPONI ARIA (golimumab) for the treatment of patients with psoriatic arthritis as well as ankylosing spondylitis. SIMPONI ARIA is fully humanised anti-tumour necrosis factor alpha therapy.
Request for table of Content at: https://www.psmarketresearch.com/market-analysis/ankylosing-spondylitis-therapeutics-pipeline-analysis/toc-sample
Some of the companies having a pipeline of ankylosing spondylitis therapeutics include, AbbVie Inc., Sanofi SA, Centocor Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Janssen Research & Development, LLC, Novartis AG, Amgen plc, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Merck Sharp & Dohme Corp., Galapagos NV, Celgene Corporation, Shanghai Pharmaceuticals Holding Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Pfizer Inc., UCB Pharma SA, Eli Lilly and Company, Eisai Co., Ltd., Korea Otsuka Pharmaceutical Co., Ltd., Inflexxion Inc. and Johnson & Johnson Pvt. Ltd.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-free: +1-888-778-7886 (USA/Canada)